Patients with the neurodegenerative disease ALS face a grim prognosis with few treatment choices. The nonprofit ALS Emergency Treatment Fund is trying to provide new alternatives to these patients through the use of so-called expanded access programs. We spoke to Jess Rabourn, managing director of the ALS Emergency Treatment Fund, about the regulations surrounding expanded access programs, how his organization gets experimental drugs into the hands of patients, and why drug makers’ view of these programs is evolving.

Listen to the podcast here.

Thanks to The Burrill Report for this podcast.

Burrill Report

1 thought on “Expanding Access to Experimental ALS Drugs: Jess Rabourn Talks ALS Emergency Treatment Fund”

  1. La colonne de gauche, nommée pilier de la Rigueur ou de la Justice,
    a une polarité féminine et représente la pressure de contraction.

Comments are closed.